BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28372872)

  • 41. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
    Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Connor JP; O'Shea A; McCool K; Sampene E; Barroilhet LM
    Gynecol Oncol; 2018 Nov; 151(2):294-298. PubMed ID: 30201233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
    Feuer GA; Lakhi N; Barker J; Salmieri S; Burrell M
    Gynecol Oncol; 2013 Dec; 131(3):520-4. PubMed ID: 24080421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.
    Dinkelspiel HE; Tergas AI; Zimmerman LA; Burke WM; Hou JY; Chen L; Hillyer G; Neugut AI; Hershman DL; Wright JD
    Gynecol Oncol; 2015 May; 137(2):203-9. PubMed ID: 25703674
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Garcia C; Yao A; Camacho F; Balkrishnan R; Cantrell LA
    Gynecol Oncol; 2017 Aug; 146(2):346-350. PubMed ID: 28499649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
    Seagle BL; Graves S; Strohl AE; Shahabi S
    Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
    Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
    Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.
    Cliby WA; Powell MA; Al-Hammadi N; Chen L; Philip Miller J; Roland PY; Mutch DG; Bristow RE
    Gynecol Oncol; 2015 Jan; 136(1):11-7. PubMed ID: 25449311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
    Matsuo K; Huang Y; Zivanovic O; Shimada M; Machida H; Grubbs BH; Roman LD; Wright JD
    Gynecol Oncol; 2019 Sep; 154(3):505-515. PubMed ID: 31279493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
    Chern JY; Curtin JP
    Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
    Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Soegaard CH; Soegaard-Andersen E; Hoegdall C
    Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of neighborhood-level socioeconomic status on racial differences in ovarian cancer treatment in a population-based analysis in Chicago.
    Joslin CE; Brewer KC; Davis FG; Hoskins K; Peterson CE; Pauls HA
    Gynecol Oncol; 2014 Nov; 135(2):285-91. PubMed ID: 25173584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    Rauh-Hain JA; Foley OW; Winograd D; Andrade C; Clark RM; Vargas RJ; Hinchcliff EM; Esselen KM; Horowitz NS; del Carmen MG
    Am J Obstet Gynecol; 2015 May; 212(5):600.e1-8. PubMed ID: 25514761
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Schuurman MS; Kruitwagen RFPM; Portielje JEA; Roes EM; Lemmens VEPP; van der Aa MA
    Gynecol Oncol; 2018 May; 149(2):270-274. PubMed ID: 29514738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
    Taşkın S; Güngör M; Ortaç F; Öztuna D
    Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.